Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/37046
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFERNANDES, Jennifer Marx
dc.contributor.authorJANDREY, Elisa Helena Farias
dc.contributor.authorKOYAMA, Fernanda Christtanini
dc.contributor.authorLEITE, Katia Ramos Moeira
dc.contributor.authorCAMARGO, Anamaria Aranha
dc.contributor.authorCOSTA, Erico Tosoni
dc.contributor.authorPEREZ, Rodrigo Oliva
dc.contributor.authorASPRINO, Paula Fontes
dc.date.accessioned2020-08-20T13:26:14Z-
dc.date.available2020-08-20T13:26:14Z-
dc.date.issued2020
dc.identifier.citationDISEASES OF THE COLON & RECTUM, v.63, n.7, p.918-926, 2020
dc.identifier.issn0012-3706
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37046-
dc.description.abstractBACKGROUND: Neoadjuvant chemoradiation for locally advanced rectal cancer combining 5-fluorouracil with radiation increases tumor regression compared with radiation alone. However, it occurs at the cost of significant treatment-related toxicity. Patients with rectal cancer using metformin have been associated with improved response to radiotherapy. OBJECTIVE: The purpose of this study was to evaluate the radiosensitizing effects of metformin in vitro and in vivo and compare it with a standard combination of radiation/5-fluorouracil. DESIGN: Colorectal cancer cell lines SW480, HT29, and HCT116 were used as models. Cell viability was compared under treatments with radiation, radiation/5-fluorouracil, metformin, radiation/metformin, and radiation/5-fluorouracil/metformin. Nude mice were injected subcutaneously with SW480 cells and treated for 1 week with radiation/5-fluorouracil, metformin, radiation/metformin, or radiation/5-fluorouracil/metformin. Tumor volume was evaluated for 4 weeks after treatment completion. The phosphorylation status of key proteins of the PI3K/Akt/mTOR pathway was determined by immunoblots. SETTINGS: This was an experimental study conducted in vitro and in vivo. PATIENTS: Animal models/cell lines were used. MAIN OUTCOME MEASURES: The end point was to investigate how metformin compares with 5-fluorouracil as a radiosensitizer. RESULTS: All cell lines significantly decreased cell viability after treatment with radiation/metformin when compared with radiation alone. Radiation/metformin was superior to radiation/5-fluorouracil in SW480 (37% vs 74%; p < 0.001). In HT29 and in HCT116, radiation/metformin was inferior to radiation/5-fluorouracil (40.0% vs 13.8%, p < 0.001 and 40.0% vs 7.0%, p < 0.001), mainly because of increased 5-fluorouracil toxicity (<= 20% of cell viability). In vivo assays indicated that radiation/metformin treatment was comparable with radiation/5-fluorouracil (557 vs 398 mm(3); p > 0.05) and that the addition of metformin to the standard radiation/5-fluorouracil did not improve tumor response (349 mm(3); p > 0.05). Metformin exerted strong PI3K/Akt/mTOR pathway inactivation effects after 24-hour exposure (increasing pAMPK, p < 0.01; decreasing pAkt, p < 0.01; and pS6, p <0.05). LIMITATIONS: In vitro and in vivo chemoradiation regimens cannot be directly translated to human delivery methods. CONCLUSIONS: Metformin enhances tumor response to radiation in vitro and in vivo. Metformin is an attractive alternative radiosensitizing agent to be considered in future studies/trials. See Video Abstract at http://links.lww.com/DCR/B219.eng
dc.description.sponsorshipLudwig Institute for Cancer Research
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
dc.description.sponsorshipCoordination for the Improvement of Higher Education Personnel
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofDiseases of the Colon & Rectum
dc.rightsrestrictedAccesseng
dc.subjectMetformineng
dc.subjectNeoadjuvancyeng
dc.subjectRadiosensitizing agenteng
dc.subject.othershort-course radiotherapyeng
dc.subject.othermolecular-mechanismseng
dc.subject.otherrandomized-trialeng
dc.subject.otherchemoradiationeng
dc.subject.otherchemoradiotherapyeng
dc.subject.otherchemotherapyeng
dc.subject.otherapoptosiseng
dc.subject.othertherapyeng
dc.subject.othergrowtheng
dc.subject.otherwatcheng
dc.titleMetformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancereng
dc.typearticleeng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.description.conferencedateJUN 01-05, 2019
dc.description.conferencelocalCleveland, OH
dc.description.conferencenameAnnual Scientific Meeting of the American-Society-of-Colon-and-Rectal-Surgeons (ASCRS)
dc.identifier.doi10.1097/DCR.0000000000001626
dc.identifier.pmid32229782
dc.subject.wosGastroenterology & Hepatologyeng
dc.subject.wosSurgeryeng
dc.type.categoryarticle; proceedings papereng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalFERNANDES, Jennifer Marx:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalJANDREY, Elisa Helena Farias:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalKOYAMA, Fernanda Christtanini:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalLEITE, Katia Ramos Moeira:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalCAMARGO, Anamaria Aranha:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalCOSTA, Erico Tosoni:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalASPRINO, Paula Fontes:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.description.beginpage918
hcfmusp.description.endpage926
hcfmusp.description.issue7
hcfmusp.description.volume63
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000540811600014
hcfmusp.origem.id2-s2.0-85086052208
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAnsari N, 2017, ANN SURG, V265, P882, DOI 10.1097/SLA.0000000000001987eng
hcfmusp.relation.referenceAppelt AL, 2013, INT J RADIAT ONCOL, V85, P74, DOI 10.1016/j.ijrobp.2012.05.017eng
hcfmusp.relation.referenceBettoni F, 2017, ANN SURG, V265, pE4, DOI 10.1097/SLA.0000000000001937eng
hcfmusp.relation.referenceBosset JF, 2005, J CLIN ONCOL, V23, P5620, DOI 10.1200/JCO.2005.02.113eng
hcfmusp.relation.referenceBujko K, 2006, BRIT J SURG, V93, P1215, DOI 10.1002/bjs.5506eng
hcfmusp.relation.referenceCao ZY, 2014, ONCOL LETT, V7, P1260, DOI 10.3892/ol.2014.1856eng
hcfmusp.relation.referenceDattani M, 2018, ANN SURG, V268, P955, DOI 10.1097/SLA.0000000000002761eng
hcfmusp.relation.referenceDeng XS, 2012, CELL CYCLE, V11, P367, DOI 10.4161/cc.11.2.18813eng
hcfmusp.relation.referenceFeoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379eng
hcfmusp.relation.referenceGarcia-Aguilar J, 2015, LANCET ONCOL, V16, P1537, DOI 10.1016/S1470-2045(15)00215-6eng
hcfmusp.relation.referenceGarcia-Aguilar J, 2015, LANCET ONCOL, V16, P957, DOI 10.1016/S1470-2045(15)00004-2eng
hcfmusp.relation.referenceHabr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32eng
hcfmusp.relation.referenceHabr-Gama A, 2019, ANN SURG, V269, P102, DOI 10.1097/SLA.0000000000002447eng
hcfmusp.relation.referenceHabr-Gama A, 2013, DIS COLON RECTUM, V56, P1109, DOI 10.1097/DCR.0b013e3182a25c4eeng
hcfmusp.relation.referenceHabr-Gama A, 2009, DIS COLON RECTUM, V52, P1927, DOI 10.1007/DCR.0b013e3181ba14edeng
hcfmusp.relation.referenceKoritzinsky M, 2015, INT J RADIAT ONCOL, V93, P454, DOI 10.1016/j.ijrobp.2015.06.003eng
hcfmusp.relation.referenceKoyama FC, 2018, BRIT J SURG, V105, pE192, DOI 10.1002/bjs.10695eng
hcfmusp.relation.referenceLan B, 2017, FRONT BIOSCI-LANDMRK, V22, P248, DOI 10.2741/4484eng
hcfmusp.relation.referenceLi M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01039eng
hcfmusp.relation.referenceMaas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8eng
hcfmusp.relation.referenceManning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001eng
hcfmusp.relation.referenceMhaidat NM, 2014, ONCOL LETT, V8, P699, DOI 10.3892/ol.2014.2211eng
hcfmusp.relation.referenceMillis SZ, 2016, JAMA ONCOL, V2, P1565, DOI 10.1001/jamaoncol.2016.0891eng
hcfmusp.relation.referenceMogavero A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16149-zeng
hcfmusp.relation.referenceMouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013eng
hcfmusp.relation.referenceMuzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252eng
hcfmusp.relation.referenceNgan SY, 2012, J CLIN ONCOL, V30, P3827, DOI 10.1200/JCO.2012.42.9597eng
hcfmusp.relation.referenceSauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694eng
hcfmusp.relation.referenceSharma V, 2009, BRIT J PHARMACOL, V157, P907, DOI 10.1111/j.1476-5381.2009.00267.xeng
hcfmusp.relation.referenceSkinner HD, 2013, CANCER MED-US, V2, P99, DOI 10.1002/cam4.54eng
hcfmusp.relation.referencevan der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-Xeng
hcfmusp.relation.referenceViollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386eng
hcfmusp.relation.referenceYu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-yeng
hcfmusp.relation.referenceZakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549-010-0763-9eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1530-0358
hcfmusp.citation.scopus10-
hcfmusp.scopus.lastupdate2022-04-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.